Promising therapies that might shift Wet Age-related Macular Degeneration Market in the next decade

With no effective cure in Wet Age-related macular degeneration (Wet AMD) treatment market, the need of new therapies that can not only slow down the progression of the vision loss but also kill the cause behind the degeneration of the macula. The present treatment approach requires intravitreal injection of anti-VEGF chemical to halt the development of extra blood vessels over macula that deteriorate the vision, which is one of the biggest Wet Age-related macular degeneration treatment market barriers. 

However, with the rise in geriatric population, and advancement in R&D, the number of companies fueling the wet-age related treatment market has increased in the years. With several clinical trials ongoing and completed, a good number of pharma players are investing in wet age-related macular degeneration treatment market. Some of them include Allergan, Bioeq, Alkahest, GrayBug Vision, Eye point pharma, Innovent Biologics, Kodiak Sciences, Opthea PanOptica, Adverum Biotechnologies and several others. 

Herein are some of the therapies in the Wet Age-related macular degeneration pipeline that are anticipated to bring a positive change in the Wet AMD treatment market in the next decade. 

Name: Abicipar pegol
Company: Allergan
MoA: Vascular endothelial growth factor A inhibitors
Status: Phase III
RoA: Intra‐vitreal injection

Name: FYB201
Company: Bioeq
MoA: Vascular endothelial growth factor A inhibitors
Status: Phase III Completed
RoA: Intra‐vitreal injection.

Name: GB-102
Company: Graybug Vision
MoA: Vascular endothelial growth factor A inhibitors
Status: Phase IIb
RoA: Intravitreal injection

Name: Vorolanib
Company: EyePoint Pharmaceuticals
MoA: Vascular endothelial growth factor receptor antagonists
Status: Phase II
RoA: Oral therapy

Name: IBI 302
Company: Innovent Biologics
MoA: Anti-VEGF therapy
Status: Phase I
RoA: Intravitreal injection

Name: KSI-301
Company: Kodiak Sciences
MoA: Novel anti-VEGF biologic
Status: Phase 1b
RoA: Intravitreal injections

Name: OPT-302
Company: Opthea
MoA: VEGF-A inhibitor
Status: Phase IIb
RoA: Intravitreal administration

Name: PAN-90806
Company: PanOptica
MoA: Tyrosine kinase inhibitor
Status: Phase 1/2
RoA: Anti-VEGF Eye Drop

Name: ADVM-022
Company: Adverum Biotechnologies
MoA: AAV-anti-VEGF gene therapy
Status: Phase 1/2
RoA: Intravitreal (IVT) administration

As per DelveInsight’s analysis, of all the Wet AMD emerging therapies, the most anticipated product to get launched is Abicipar Pegol, a lead candidate of Allergan. With several other therapies in the horizon to get launched, the Wet Age-related macular degeneration treatment market is anticipated to increase at an advanced pace in the forecast period.